Journal of Clinical Endocrinology & Metabolism, Vol 67, 1025-1030, Copyright © 1988 by Endocrine Society

ARTICLES

The effect of single oral doses of prednisone on the circadian rhythm of serum osteocalcin in normal subjects

HK Nielsen, P Charles and L Mosekilde
Department of Clinical Physiology and Nuclear Medicine, Arhus Kommunehospital, Denmark.

Serum osteocalcin (OC), which is a sensitive marker of bone formation, is reduced during chronic glucocorticoid treatment in accordance with the finding of reduced bone formation, and even short term glucocorticoid treatment reduces serum OC. In a double blind placebo- controlled study, we measured the effects of 2.5 and 10 mg prednisone, orally, on the circadian variation of serum OC in 15 normal subjects (8 women and 7 men), aged 22-46 yr. All subjects were studied twice at an interval of 1 week. Blood samples were collected every 60 min from 1630 until 1700 h the following day. Prednisone or placebo was given at 2000 h. Serum OC was measured by an in-house RIA. After placebo administration serum OC increased from 2230 h to a peak value around 0230 h, followed by a gradual decline to a nadir around 1500 h. Both doses of prednisone inhibited and even reversed the nocturnal rise in serum OC levels; the inhibition occurred within 3-4 h. There was no significant difference in the time from prednisone ingestion to maximal decrease (7.2 h vs. 9.8 h) or in the maximal decrease (52% vs. 54%). However, the duration of the inhibition was significantly shorter after 2.5 mg than after 10 mg prednisone (approximately 6 h vs. 12 h; (p less than 0.01). We conclude that serum OC is sensitive to small doses of prednisone, and that serial serum OC measurements may be a sensitive marker of the effect of exogenous glucocorticoids on osteoblastic activity in vivo.

This article has been cited by other articles:

				A. Dovio, L. Perazzolo, L. Saba, A. Termine, M. Capobianco, A. Bertolotto, and A. Angeli High-dose glucocorticoids increase serum levels of soluble IL-6 receptor {alpha} and its ratio to soluble gp130: an additional mechanism for early increased bone resorption. Eur. J. Endocrinol., May 1, 2006; 154(5): 745 - 751. [Abstract] [Full Text] [PDF]

				A. Dovio, L. Perazzolo, G. Osella, M. Ventura, A. Termine, E. Milano, A. Bertolotto, and A. Angeli Immediate Fall of Bone Formation and Transient Increase of Bone Resorption in the Course of High-Dose, Short-Term Glucocorticoid Therapy in Young Patients with Multiple Sclerosis J. Clin. Endocrinol. Metab., October 1, 2004; 89(10): 4923 - 4928. [Abstract] [Full Text] [PDF]

				P C Ng, C W K Lam, G W K Wong, C H Lee, P S Cheng, T F Fok, I H S Chan, E Wong, K Cheung, and S Y Lee Changes in markers of bone metabolism during dexamethasone treatment for chronic lung disease in preterm infants Arch. Dis. Child. Fetal Neonatal Ed., January 1, 2002; 86(1): F49 - 54. [Abstract] [Full Text] [PDF]

				H. M. Heshmati, B. L. Riggs, M. F. Burritt, C. A. McAlister, P. C. Wollan, and S. Khosla Effects of the Circadian Variation in Serum Cortisol on Markers of Bone Turnover and Calcium Homeostasis in Normal Postmenopausal Women J. Clin. Endocrinol. Metab., March 1, 1998; 83(3): 751 - 756. [Abstract] [Full Text]